Dr. Tzachanis on Research Regarding Post-CAR T-Cell Therapy Progression in Lymphoma

Dimitrios Tzachanis, MD, PhD, discusses research regarding post–CAR T-cell therapy progression in lymphoma.

Dimitrios Tzachanis, MD, PhD, hematologist/medical oncologist and assistant professor of medicine, University of California, San Diego Health, discusses research regarding post——CAR T-cell therapy progression in lymphoma.

Patients with lymphoma who progress on CAR T-cell therapy typically have poor outcomes, says Tzachanis.

At the 2019 ASH Annual Meeting, data from the multicenter phase I/Ib GO29781 study showed that the CD3- and CD20-targeted bispecific antibody mosunetuzumab elicited durable responses in patients with highly refractory non-Hodgkin lymphoma. Moreover, the complete remission rate among patients who had previously received CAR T-cell therapy was 22.2%.

Apart from bispecific antibodies, which have shown early efficacy in this space, allogeneic stem cell transplant could also be considered if the disease is under control, concludes Tzachanis.

Related Videos
View All
Related Content